menu
    • menu
    [{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MDX2001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ModeX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ModeX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MDX2004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ModeX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ModeX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"MDX2202","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ModeX Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"ModeX Therapeutics \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"ModeX Therapeutics \/ BARDA"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"OPKO Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ModeX Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.29999999999999999,"dosageForm":"Inhalation","sponsorNew":"ModeX Therapeutics \/ OPKO Health","highestDevelopmentStatusID":"4","companyTruncated":"ModeX Therapeutics \/ OPKO Health"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ModeX Therapeutics \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"ModeX Therapeutics \/ BARDA"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"ModeX Therapeutics","amount2":1,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"ModeX Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"ModeX Therapeutics \/ Regeneron Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by ModeX Therapeutics

    Menu

    ModeX Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : $1,000.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Opko Health's ModeX Collaborates with Regeneron for Multispecific Antibodies

                            Details : The collaboration aims to advance an undisclosed antibody in the field of immunology.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $7.0 million

                            October 29, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : $1,000.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDX2004

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation and Dose Expansion Study of MDX2004 in Participants with Advanced Tumors

                            Details : MDX2004 is a Antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 07, 2025

                            Lead Product(s) : MDX2004

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDX2202

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : BARDA

                            Deal Size : $110.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ModeX Secures $35M For COVID Antibodies, $16M For Influenza Program

                            Details : The funding will support the development of a novel multispecific antibody to SARS-CoV-2 from preclinical and influenza multispecifics with gene and/or protein delivery modalities.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 07, 2024

                            Lead Product(s) : MDX2202

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : BARDA

                            Deal Size : $110.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDX2001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

                            Details : MDX2001 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Biliary Tract Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 02, 2024

                            Lead Product(s) : MDX2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : BARDA

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious D...

                            Details : The agreement aims to advance a platform and specific candidates addressing a range of viral infectious diseases and will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 28, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : BARDA

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            ModeX Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : OPKO Health

                            Deal Size : $300.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology a...

                            Details : ModeX Therapeutics has developed highly flexible multi-specific antibody technology platforms with broad targeting and functional capabilities, simpler manufacturing and potentially better specificity and safety, providing significant differentiation fro...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 09, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : OPKO Health

                            Deal Size : $300.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth